Subcutaneous immunotherapy for the treatment of allergies: a review of the clinical efficacy, safety and guidelines
CADTH
Record ID 32012000698
English
Authors' recommendations:
Some marginal beneficial effect of subcutaneous immunotherapy (SCIT) was found in the treatment of patients with asthma or rhinitis compared with placebo; however, no evidence on SCIT in comparison with placebo, antihistamine or
SLIT was from Canada. Existing guidelines recommended that SCIT can only be used as a "third line treatment" after avoidance allergen and conventional pharmacotherapy, and the adverse events including anaphylaxis must be fully discussed with patients; however, no Canadian guidelines on SCIT was identified.
Details
Project Status:
Completed
Year Published:
2012
URL for published report:
http://www.cadth.ca/media/pdf//htis/aug-2012/RC0375%20Allergy%20Serums%20Final.pdf
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Canada
MeSH Terms
- Injections, Subcutaneous
- Hypersensitivity
Contact
Organisation Name:
Canadian Agency for Drugs and Technologies in Health
Contact Address:
600-865 Carling Avenue, Ottawa, ON K1S 5S8 Canada. Tel: +1 613 226 2553; Fax: +1 613 226 5392;
Contact Name:
requests@cadth.ca
Contact Email:
requests@cadth.ca
Copyright:
Canadian Agency for Drugs and Technologies in Health (CADTH)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.